Immunoreactivity of 14F7 Mab in Digestive System Tumors
Author Information
Author(s): Blanco Rancés, Rengifo Enrique, Cedeño Mercedes, Rengifo Charles E., Alonso Daniel F., Carr Adriana
Primary Institution: Center of Molecular Immunology, Havana, Cuba
Hypothesis
The study evaluates the immunorecognition of 14F7 Mab against N-Glycolyl GM3 ganglioside in digestive system tumors.
Conclusion
The 14F7 Mab showed significant immunoreactivity in various malignant tissues of the digestive system, suggesting its potential as a target for immunotherapy.
Supporting Evidence
- 14F7 Mab showed reactivity in all adenocarcinomas of the stomach, colon, and pancreas.
- Immunoreactivity was not observed in normal tissues except for a few cases in peritumoral areas.
- More than 90% of hepatocellular carcinomas showed moderate to intense immunostaining with 14F7 Mab.
Takeaway
This study looked at how a special antibody can find cancer cells in the stomach and intestines, which could help doctors treat these cancers better.
Methodology
Immunohistochemical assays were performed on formalin-fixed and paraffin-embedded tissue samples from 72 primary human tumors and 25 normal tissues.
Limitations
The study did not distinguish changes in NeuGcGM3 expression associated with histopathological grade in stomach and pancreas tumors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website